Page last updated: 2024-09-04
cd 437 and celastrol
cd 437 has been researched along with celastrol in 1 studies
Compound Research Comparison
| Studies (cd 437) | Trials (cd 437) | Recent Studies (post-2010) (cd 437) | Studies (celastrol) | Trials (celastrol) | Recent Studies (post-2010) (celastrol) |
|---|---|---|---|---|---|
| 134 | 0 | 26 | 885 | 1 | 741 |
Protein Interaction Comparison
| Protein | Taxonomy | cd 437 (IC50) | celastrol (IC50) |
|---|---|---|---|
| Telomerase reverse transcriptase | Homo sapiens (human) | 0.78 | |
| Ubiquitin carboxyl-terminal hydrolase 2 | Homo sapiens (human) | 6.8 | |
| Ubiquitin carboxyl-terminal hydrolase isozyme L1 | Homo sapiens (human) | 6.8 | |
| Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | 8.41 | |
| Ubiquitin carboxyl-terminal hydrolase isozyme L3 | Homo sapiens (human) | 6.8 | |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 3.45 | |
| Tyrosine-protein phosphatase non-receptor type 6 | Homo sapiens (human) | 3.1 | |
| Tyrosine-protein phosphatase non-receptor type 11 | Homo sapiens (human) | 3.5667 | |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 0.25 | |
| Regulator of G-protein signaling 17 | Homo sapiens (human) | 6.1795 | |
| Ubiquitin carboxyl-terminal hydrolase 15 | Homo sapiens (human) | 6.8 | |
| Ubiquitin carboxyl-terminal hydrolase isozyme L5 | Homo sapiens (human) | 6.8 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Chen, K; Fang, M; Guo, K; He, F; Huang, J; Li, B; Lin, Z; Liu, S; Wu, Q; Wu, Z; Yao, J; Zeng, J | 1 |
Other Studies
1 other study(ies) available for cd 437 and celastrol
| Article | Year |
|---|---|
Design, synthesis, and biological evaluation of 5-((8-methoxy-2-methylquinolin-4-yl)amino)-1H-indole-2-carbohydrazide derivatives as novel Nur77 modulators.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Design; Humans; Hydrazines; Kaplan-Meier Estimate; Liver Neoplasms; Mice; Molecular Docking Simulation; Nuclear Receptor Subfamily 4, Group A, Member 1; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2020 |